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Abstract
Rationale —  The cannabinoid CB1 receptor antagonist/inverse 
agonist rimonabant (SR 141716) has been shown to block 
reinforcing and rewarding effects of nicotine. Research 
has not investigated whether the cannabinoid system is 
involved in the interoceptive stimulus effects of nicotine 
functioning as a conditional stimulus (CS). 
Objective  — We examined the effects of rimonabant and the 
CB1/2 receptor agonist, CP 55,940, on responding evoked 
by a nicotine CS in rats. Additionally, we determined 
whether CP 55,940 functioned as a CS or a Pavlovian posi-
tive drug feature 
Materials and methods  — Pavlovian discrimination training in-
volved intermixed nicotine (0.2 mg base/kg) and saline 
sessions with intermittent access to water only on nicotine. 
Antagonism tests with rimonabant (0.1-3 mg/kg) and sub-
stitution tests with CP 55,940 (0.003–0.1 mg/kg) followed. 
An effective dose of CP 55,940 was tested against the nic-
otine generalization curve. A separate group received CS 
training with CP 55,940 (0.01 mg/kg). Two other groups 
were trained using CP 55,940 (0.01 or 0.03 mg/kg) as a pos-
itive drug feature in which a brief light CS signaled access 
to water only on CP 55,940 sessions 
Results  — Rimonabant blocked nicotine-evoked responding. 
CP 55,940 partially substituted for nicotine and enhanced 
responding to lower nicotine doses. Overall, CP 55,940 did 
not acquire control of conditioned responding in either 
Pavlovian drug discrimination task 
Conclusions  — The cannabinoid system was involved in the 
CS effects of nicotine. This finding is counter to the operant 
drug discrimination research with nicotine as a discrimina-
tive stimulus, warranting further research into this possi-
ble dissociation. 
Keywords:  appetitive conditioning, associative learning, can-
nabinoid receptor, nicotinic acetylcholine, occasion setting, 
smoking cessation 
Introduction
Recent attention has been given to cannabinoid com-
pounds for use in smoking cessation. Of particular in-
terest have been compounds related to the cannabinoid 
CB1 receptor antagonist/inverse agonist rimonabant, 
or SR 141716. Cannabinoid antagonists have appeared 
promising for use as smoking pharmacotherapies, and 
several pharmaceutical companies have worked to de-
velop a marketable compound. For example, another 
CB1 antagonist, surinabant (SR 147778; Lamota et al. 
2008; Rinaldi-Carmona et al. 2004) completed Phase II 
clinical trials in Europe in 2008 before development was 
discontinued because of adverse side effects. 
Preclinical findings in rodents describing the role of 
cannabinoid activation on behavioral effects of nico-
tine have been reviewed elsewhere (e.g., Beardsley and 
Thomas 2005; Castañé et al. 2005). Briefly, rimonabant 
has been found to decrease nicotine self-administration 
(Cohen et al. 2002; Kodas et al. 2007), cue-induced rein-
statement of nicotine seeking (Cohen et al. 2004; De Vr-
ies et al. 2005), and nicotine-conditioned place prefer-
ences (Forget et al. 2005; Le Foll and Goldberg 2004). 
The operant discriminative stimulus (SD) effects of nic-
otine do not appear to be affected by pretreatment with 
rimonabant (Cohen et al. 2002; Le Foll and Goldberg 
2004; Zaniewska et al. 2006). 
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These cannabinoid effects on nicotine led us to exam-
ine the potential role for cannabinoid activation in the 
expression of the conditional stimulus (CS) effects of 
nicotine in an appetitive Pavlovian conditioning task (cf. 
Besheer et al. 2004). In this task, rats receive a subcuta-
neous (SC) injection of nicotine or saline before place-
ment in a conditioning chamber. On nicotine sessions, 
liquid sucrose (i.e., the unconditioned stimulus; US) is 
delivered intermittently. Sucrose is not available on in-
termixed saline sessions. Using head entries into the 
sucrose receptacle before the first sucrose delivery as 
a measure of the conditioned response (i.e., CR; goal 
tracking; Farwell and Ayres 1979), nicotine serves as an 
interoceptive CS as evidenced by increased dipper en-
tries on nicotine compared to saline sessions. The most 
notable procedural distinction between this task and the 
operant drug discrimination models is that there is no 
explicit response requirement for reinforcement to be 
delivered in the discriminated goal-tracking task. Al-
though a rat must insert its head into the dipper to ac-
cess the sucrose, the delivery of the sucrose is deter-
mined by the experimenter—not the rat. Recent research 
suggests that the CS effects of nicotine might involve 
somewhat different neuropharmacological processes 
than that of a SD. Specifically, N-methyl-d-aspartate re-
ceptor blockade attenuated conditioned responding 
evoked by a nicotine CS (Murray and Bevins 2007a), but 
has not been shown to affect operant responding con-
trolled by SD effects of nicotine (Kim and Brioni 1995; 
Zakharova et al. 2005).Therefore, we examined the ef-
fects of the cannabinoid CB1 receptor antagonist/inverse 
agonist, rimonabant (Pan et al. 1998; Rinaldi-Carmona et 
al. 1994) and the non-selective cannabinoid CB1/2 recep-
tor agonist, CP 55,940 (Little et al. 1988; Thomas et al. 
1998) on nicotine-evoked conditioned responding. We 
also examined whether CP 55,940 served as a CS or as a 
Pavlovian drug feature. 
Materials and methods
Subjects   For all experiments, we used male Sprague–
Dawley rats (314 ± 10 g at start of study) from Harlan 
(Indianapolis, IN, USA) that were previously used in 
brief cocaine/novelty place conditioning experiments 
(Reichel and Bevins 2008; unpublished research). Rats 
were taken from control and low-dose cocaine groups; 
care was taken to match histories as much as possible 
across the different conditions of the present report. Be-
fore the start of the present studies, rats were handled 
for at least 3 min/day for 3 days. They were housed in-
dividually in clear 48.3 × 26.7 × 20.3 cm (l × w × h) poly-
carbonate cages lined with wood shavings in a tem-
perature- and humidity-controlled colony. Food was 
continuously available in the home cage. Rats were 23-
h water-restricted; access to water for the hour occurred 
after each daily session. All sessions were conducted 
during the light portion of a 12-h light:dark cycle with 
lights on at 0600 h. Protocols were approved by the Uni-
versity of Nebraska-Lincoln Animal Care and Use Com-
mittee and followed the “Guidelines for the Care and 
Use of Mammals in Neuroscience and Behavioral Re-
search” (National Research Council 2003). 
Apparatus   Eight conditioning chambers (ENV-008CT; 
Med Associates, Inc., St. Albans, VT, USA) measuring 
30.5 × 24.1 × 21.0 cm (l × w × h) were used. Sidewalls 
were aluminum; the ceiling and front and back walls 
were clear polycarbonate. Each chamber was equipped 
with a recessed receptacle (5.2 × 5.2 × 3.8 cm; l × w × d) 
on one sidewall. A dipper arm raised a 0.1-ml cup of 
distilled water into the receptacle. Water, rather than 
sucrose, served as the US because cannabinoid com-
pounds can affect caloric consumption (e.g., Glick and 
Milloy 1972; Xie et al. 2007). An infrared emitter/detec-
tor unit, 1.2 cm into the receptacle and 3 cm above the 
chamber floor, monitored head entries into the dipper. 
A second infrared emitter/detector unit, 4 cm above 
the rod floor, bisected the chamber 14.5 cm from the 
sidewall containing the receptacle. This unit provided 
a measure of locomotor activity in the chamber. Two 
white stimulus lights (2.54 cm diameter; 28 V, 100 mA) 
were each mounted on the sidewall on either side of 
the dipper receptacle, 14.6 cm above the metal rod floor 
and 3.5 cm from either the front or the back wall. Illu-
mination of the lights served as the discrete CS in the 
CP 55,940 positive feature experiments. Each chamber 
was enclosed in a light- and sound-attenuating cubicle 
fitted with a fan to provide airflow and mask noise. A 
personal computer with Med Associates interface and 
software (Med-PC for Windows, version IV) controlled 
water deliveries and recorded dipper entries and loco-
motor activity. 
Drugs   (−)-Nicotine hydrogen tartrate (Sigma, St. Louis, 
MO, USA), rimonabant (RTI International, Research Tri-
angle Park, NC, USA), and CP 55,940 (RTI International) 
were used. Nicotine was mixed in saline then adjusted 
to a pH of 7.0 ± 0.2. Rimonabant and CP 55,940 were 
mixed in a 1:1:18 Tween-80: 100% ethanol: distilled wa-
ter vehicle. Nicotine was injected subcutaneously (SC) 
at 1 ml/kg with a 5-min injection-to-placement interval 
(IPI). Rimonabant and CP 55,940 were injected intraper-
itoneally (IP). Rimonabant was given at 2 ml/kg with a 
40 min IPI (cf. Wiley et al. 1995a); CP 55,940 was given 
at a volume of 1 ml/kg with a 30 min IPI (cf. De Vry and 
Jentzsch 2003; Mauler et al. 2002). Nicotine doses are re-
ported in base form. 
Nicotine CS training and testing   Rats (n = 16) were given 
an injection of 0.2 mg/kg nicotine each day for 3 days in 
the home cage to attenuate the initial locomotor suppres-
sant effects of nicotine (cf. Murray and Bevins 2007a). 
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Daily training sessions began the day after the last nic-
otine injection. Rats received either 0.2 mg/kg nicotine 
or saline before the start of each 20-min session. During 
nicotine sessions, there were 36 deliveries of 4 s access 
to water. Four different programs that varied when wa-
ter was delivered were created to discourage timing of 
water deliveries. The average time before the first wa-
ter delivery across programs was 137 s with a range of 
124–152 s. No water was delivered during saline ses-
sions, but there were 4-s “empty” intervals to maintain 
consistency between nicotine and saline sessions. Ses-
sion types and programs were randomly assigned with 
the restriction that no more than two nicotine or two sa-
line sessions occurred in a row. Training continued for 
28 sessions. Following acquisition of the discrimination, 
rats entered testing. On the first four consecutive days 
of each 5-day cycle, rats received two nicotine and two 
saline training sessions as described previously. If the 
discrimination criterion was met (see later), a 4-min test 
session occurred in place of a training session on day 5; 
water was withheld in testing. If the criterion was not 
met, the rat remained in its home cage on that day. Nic-
otine generalization was tested first, followed by tests 
of rimonabant antagonism then CP 55,940 substitution. 
Finally, nicotine generalization was conducted again 
concurrently with CP 55,940 pretreatment of the nico-
tine dose–effect curve. Within each phase, the test doses 
were randomly intermixed for each rat. All ligands and 
doses in a phase were completed before beginning the 
next phase. 
CP 55,940 CS training   A separate set of rats (n = 16) re-
ceived either 0.01 mg/kg CP 55,940 or vehicle before 
each 20-min session. Water was delivered only in the CP 
55,940 sessions. The programs and their order were the 
same as the nicotine CS experiment. Following 56 ses-
sions of training with the CP 55,940 CS, rats were ran-
domly assigned to one of two groups. One group re-
mained with CP 55,940 training as described for another 
eight CP 55,940 and eight vehicle sessions. The other 
group was switched from CP 55,940 training to 0.2 mg/
kg nicotine training for eight nicotine and eight saline 
sessions. 
CP 55,940 feature-positive training   Rats (0.01/0.03 mg/
kg group, n = 14; 0.03 mg/kg group, n = 6) received dip-
per training consisting of three 50-min sessions. Each 
daily session was initiated with the rat’s first head entry 
into the receptacle. The probability of receiving 4 s ac-
cess to water decreased from 0.267 to 0.05 per 60 s over 
the three sessions. Acquisition training began the day 
after the last dipper training session. Rats were injected 
with CP 55,940 or vehicle 30-min before chamber place-
ment. During each 20-min session, there were eight 15-s 
light CS presentations. On CP 55,940 sessions, each off-
set of the light was followed immediately by 4-s access 
to water. Four different programs were used to vary the 
timing of light presentations and water delivery. The 
average time to the first light onset was 135 s (range of 
90–180 s) with a mean intertrial interval of 120 s (range 
of 74–165 s). On vehicle sessions, light presentations 
were matched with those of CP 55,940 sessions and 4-s 
“empty” intervals occurred in place of water deliveries 
to ensure identical session length. CP 55,940 and vehi-
cle sessions were intermixed randomly with the restric-
tions that no more than two of a session type occurred 
in a row. The 0.01/0.03 mg/kg group received 60 train-
ing sessions at 0.01 mg/kg followed by 60 training ses-
sions at 0.03 mg/kg CP 55,940; the 0.03 mg/kg group re-
ceived 120 training sessions. 
Dependent measures   In the CS experiments, the primary 
dependent measure was rate of dipper entries per sec-
ond before the first water delivery. To allow for compa-
rable measurement between drug (i.e., water) and ve-
hicle (i.e., no water) sessions, the program types were 
matched for timing of the intervals from which the dip-
per entry rate was taken. The dependent measure for 
test sessions was the dipper entry rate in the first 2 min 
of the test. To qualify to test, dipper entry rate on each 
nicotine session was a minimum of 0.01 entries per sec-
ond higher than each saline session within that testing 
cycle. Rate of locomotor activity in the chamber (beam 
breaks per second during the same interval as used for 
dipper entries) was also analyzed. In feature-positive 
experiments, the primary dependent measure was the 
initial elevation score of a session. This score was cal-
culated as the number of dipper entries recorded dur-
ing the first 15-s presentation of the light CS minus the 
number of dipper entries recorded during the 15-s inter-
val before the light (CS period–pre-CS period). A posi-
tive value indicates more dipper entries during the CS. 
Locomotor activity was also recorded throughout the 
session. 
Data analyses   For acquisition, two-way repeated mea-
sures analyses of variance (ANOVAs) were conducted 
with Drug (nicotine versus saline or CP 55,940 versus 
vehicle) as one factor and Session as the other factor for 
the dipper entry and activity measures. Generalization, 
antagonism, and substitution tests were analyzed with 
one-way repeated measures ANOVAs with Drug Dose 
as the factor. Finally, the regeneration of the nicotine 
generalization curves with CP 55,940 pretreatment were 
examined with a two-way repeated measures ANOVA 
using Drug (CP 55,940 or none) as one factor and Nic-
otine Dose as the other factor. Significant effects in sub-
stitution and antagonism ANOVAs were followed with 
Tukey’s honestly significant difference (HSD) tests. Sig-
nificant interactions in the two-way acquisition ANO-
VAs prompted selective use of paired t tests with Bon-
ferroni’s correction to compare drug conditions within 
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each session. Median effective doses [ED50s (95% confi-
dence intervals)] were calculated using the least squares 
linear regressions on nicotine generalization curves and 
testing that resulted in full blockade of the CS effects of 
nicotine. Statistical significance was declared when p < 
0.05 for all tests. Only significant values are reported. 
Results
Nicotine CS training and testing   As shown in Figure 1a, 
the discrimination was acquired by the eighth day of 
training. This impression was supported by a significant 
 
 
Drug × Session interaction, F(13, 195) = 13.03, p < .001, 
followed by paired t tests with Bonferroni’s correction 
indicating that for sessions 4–14, dipper entries were 
higher on nicotine than saline sessions, ts(15) ≥ 4.38, ps 
< 0.001. Overall higher response levels on nicotine com-
pared to saline was also supported by a main effect of 
Drug, F(1, 15) = 100.49, p < 0.001. Although inspection 
of the inset graph does not suggest a systematic effect of 
nicotine on locomotor activity, there was a Drug × Ses-
sion interaction, F(13, 195) = 1.84, p < .05. However, none 
of the post-hoc comparisons were significant. 
As shown in Figure 1b, conditioned responding di-
minished as the test dose of nicotine decreased from the 
training dose (0.2 mg/kg) to saline [ED50 = 0.052 (0.03–
0.074) mg/kg]. There was a main effect of Drug Dose, 
F(5, 75) = 17.93, p < 0.001. Follow-up Tukey’s HSD tests 
found that 0.05, 0.1, and 0.2 mg/kg nicotine evoked 
greater responding than saline, and that 0, 0.025, and 0.4 
mg/kg evoked lower responding than the 0.2 mg/kg 
training dose of nicotine, HSDmmd = 0.046. There was no 
significant change in locomotor activity (inset graph) as 
a function of nicotine dose. 
Results from antagonism and substitution testing are 
shown in Figure 2. During these phases, two rats were 
removed from the study for failure to maintain the dis-
crimination (n = 14). Pretreatment with increasing doses 
of rimonabant decreased the nicotine-evoked CR (Fig-
ure 2a). The main effect of Drug Dose, F(4, 52) = 17.87, 
p < 0.001, showed 1 and 3 mg/kg rimonabant decreased 
nicotine-evoked responding compared to saline pre-
treatment, HSDmmd = 0.045 [ED50 = 1.09 (0.49–1.69) mg/
kg]. Of those two doses, 1 mg/kg was also different 
from the vehicle baseline. Relative to vehicle pretreat-
ment, the highest dose of rimonabant reduced nicotine-
induced locomotor activity (inset graph), F(4, 52) = 4.15, 
p < 0.01, to a level comparable to vehicle only, HSDmmd 
= 0.078 (i.e., no nicotine). 
There was an inverted U-shaped pattern of CP 
55,940 substitution for the nicotine CS (Figure 2b). 
There was a main effect of Drug Dose, F(4, 52) = 6.77, 
p < 0.001. Conditioned responding on 0.01 mg/kg CP 
55,940 was significantly higher than vehicle alone, HS-
Dmmd = 0.028. This dose also differed from the 0.2 mg/
kg nicotine baseline. The 0.1 mg/kg dose of CP 55,940 
reduced locomotor activity relative to vehicle alone 
and nicotine (inset graph), F(4, 52) = 6.61, p < 0.001, HS-
Dmmd = 0.06. 
The dose of CP 55,940 that partially substituted for 
the nicotine CS (0.01 mg/kg) was assessed to deter-
mine if it could shift the nicotine dose–effect curve. Dur-
ing this phase, one more rat was removed for poor dis-
crimination performance (n = 13). As shown in Figure 
2c, CP 55,940 appeared to enhance nicotine-appropri-
ate responding. There was a main effect of Drug, F(1, 
12) = 7.07, p < .001, and a Drug × Nicotine Dose inter-
action, F(3, 36) = 2.88, p < .05. CP 55,940 enhanced re-
Figure 1. Panel a shows dipper entries per second before the 
first water delivery on nicotine sessions compared to equiva-
lent time on saline sessions. * denotes significant difference be-
tween nicotine and saline sessions. The inset graph of panel a 
shows locomotor activity per second. Panel b shows dipper 
entries per second during nicotine generalization tests. *de-
notes significant difference from the 0.2 mg/kg nicotine train-
ing dose. # denotes significant difference from saline (0 mg/kg 
nicotine) responding. The inset graph of panel b shows the lo-
comotor activity per second during generalization tests 
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sponding to saline and to 0.1 mg/kg nicotine, HSDmmd 
= 0.038 [ED50s  = 0.043 (0.025–0.06) mg/kg for nicotine 
alone; 0.049 (0.022–0.075) mg/kg for CP 55,940 pretreat-
ment]. Although CP 55,940 showed partial substitution 
for the training dose of nicotine twice and enhanced re-
sponding to a low dose of nicotine, these effects did not 
translate into a shift in the ED50 for nicotine. A Type I er-
ror seems unlikely given the replication of partial sub-
stitution. The outcome may instead be a product of not 
having enough test doses along the linear portion of the 
dose–effect curves. Locomotor activity appeared rela-
tively stable across nicotine doses (inset graph). How-
ever, there was a significant Drug × Nicotine Dose in-
teraction, F(3, 36) = 5.39, p < 0.01; post-hoc comparisons 
found no differences HSDmmd = 0.069. 
CP 55,940 CS training   When CP 55,940 was trained as 
the CS, the discrimination was not acquired even when 
training continued for twice as long as the nicotine CS 
(Figure 3a). There was a significant Drug × Session in-
teraction, F(27, 405) = 1.90, p < 0.01. However, none of 
the comparisons were significant following Bonferroni’s 
correction tests. Activity (Figure 3c) was similar regard-
less of drug treatment. 
For rats that remained on CP 55,940 CS training, CP 
55,940 evoked slightly higher levels of dipper entries 
than vehicle (Figure 3b, top panel) as shown by a main 
effect of Drug, F(1, 7) = 5.87, p < 0.05. Although this re-
sult suggests potential CS effects of CP 55,940, the dis-
crimination was weak and not maintained throughout 
training. There were no differences in activity for this 
subset of rats (Figure 3d, top panel). In contrast, rats 
switched to nicotine quickly acquired the discrimination 
(Figure 3b, bottom panel). There was a significant Drug 
× Session interaction, F(7, 49) = 14.74, p < 0.001. There 
was more responding on nicotine than saline for ses-
sions 31 and 33–36, ts(7) ≥ 3.88, ps < 0.0063. For activity 
(Figure 3d, bottom panel), there was a significant Drug 
× Session interaction, F(7, 49) = 2.25, p < 0.05. Nicotine 
decreased activity on session 30, t(7) = 4.20, p < 0.0063. 
CP 55,940 feature positive training: 0.01/0.03 mg/kg group 
The light CS came to evoke a goal-tracking CR (Fig-
ure 4a). The main effect of Session supports the obser-
vation that dipper entries during the light presentations 
steadily increased, F(29, 377) = 4.48, p < 0.001. However, 
rats did not discriminate between 0.01 mg/kg CP 55,940 
sessions (water reinforced) and the vehicle sessions 
(non-reinforced). There was no main effect of Drug or 
Drug × Session interaction. After switching from 0.01 
mg/kg to 0.03 mg/kg CP 55,940, weak discrimination 
performance emerged [main effect of Drug, F(1, 13) = 
18.13, p < .001]. Response rates were stable across tri-
als resulting in no main effect of Session or Drug × Ses-
sion interaction. CP 55,940 evoked higher locomotor ac-
tivity than vehicle at both training doses (Figure 4b). For 
 
 
Figure 2. Panels a and b show dipper entries per second dur-
ing rimonabant and CP 55,940 tests, respectively. Inset graphs 
for each panel show locomotor activity per second during the 
tests. *denotes significant difference from vehicle condition of 
the given drug test. # denotes a further significant difference 
from the control baseline (no nicotine for rimonabant and 0.2 
mg/kg nicotine for CP 55,940). Panel c shows dipper entries 
per second for pretreatment of a range of nicotine doses with 
0.01 mg/kg CP 55,940. *denotes significant difference from the 
same dose of nicotine with no pretreatment. The inset graph 
shows locomotor activity per second 
660 J .  E. Mur r ay E t al. i n PsychoPharmacology  205 (2009) 
each dose, there were main effects of Drug, Fs ≥ 15.65, ps 
≤ .002, but no main effect of Session or Drug × Session 
interaction. 
CP 55940 feature positive training: 0.03 mg/kg group   Sim-
ilar to the 0.01/0.03 mg/kg group, when rats were 
trained with 0.03 mg/kg CP 55,940 from the outset a 
very weak discrimination developed (data not shown). 
There was a main effect of Drug, F(1, 295) = 6.97, p < 
0.05, with the light CS evoking slightly higher initial el-
evation scores after CP 55,940 than vehicle administra-
tion. There was no effect of Session or Drug × Session 
interaction. Locomotor activity was slightly higher on 
CP 55,940 sessions than vehicle sessions, with an over-
all decrease in activity across sessions (data not shown). 
These observations were supported by main effects of 
Drug, F(1, 5) = 7.41, p < 0.05, and Session, F(59, 295) = 
2.41, p < 0.001, and a Drug × Session interaction, F(59, 
295) = 1.39, p < 0.05. However, after Bonferrroni’s cor-
rection, none of the comparisons were significant. 
Discussion
Rats readily acquired the Pavlovian drug discrimi-
nation when 0.2 mg/kg nicotine was paired with a wa-
ter US. This finding extends previous research from our 
laboratory to a new US. Past research used food restric-
tion and a sucrose US. The studies that used 0.2 mg/kg 
nicotine as the training dose yielded similar to slightly 
higher ED50s [from 0.049 in Murray and Bevins (2007a) 
Figure 3. Panel a shows dipper entries per second during 0.01 mg/kg CP 55,940 CS training. Panel b shows dipper entries per sec-
ond for rats remaining on CP 55,940 training (top graph) and switched from CP 55,940 CS to nicotine CS training (bottom graph), 
respectively. ^ denotes a significant main effect of CP 55,940 training without an interaction. * denotes significant difference be-
tween nicotine and saline sessions. Panel c shows locomotor activity during 0.01 mg/kg CP 55,940 CS training. Panels d show lo-
comotor activity per second for rats remaining on CP 55,940 (top graph) and for rats switched from CP 55,940 to nicotine CS train-
ing (bottom graph), respectively. * denotes significant difference between nicotine and saline sessions 
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to 0.075 mg/kg in Reichel et al. (2007a)] than the 0.052 
mg/kg nicotine found in the present study. We also 
found a role for endocannabinoid activation in the ex-
pression of the interoceptive CS effects of nicotine. 
Rimonabant partially blocked the CS effects of nico-
tine without affecting locomotor activity at 1 mg/kg. At 
3 mg/kg, there was a concurrent reduction in locomo-
tion and dipper entries, a finding that is potentially con-
sistent with a response competition account of reduced 
locomotion after administration of rimonabant (Tallett 
et al. 2007). In that study, 1.5 and 3 mg/kg rimonabant 
reduced locomotion while enhancing grooming and 
scratching behaviors. Future research involving video 
recording of behavior during test sessions would be 
needed to assess this speculation. Our finding with the 1 
mg/kg dose of rimonabant complements the well-docu-
mented role of endocannabinoids in the US or reinforc-
ing effects of nicotine (e.g., Castañé et al. 2002; Kodas et 
al. 2007). However, the results are in contrast to the op-
erant drug discrimination literature. In those studies, 
rimonabant at a range of 0.3 to 3 mg/kg (Cohen et al. 
2002; Le Foll and Goldberg 2004) or even 5 to 10 mg/
kg (Zaniewska et al. 2006) did not affect the distribution 
of nicotine-appropriate responding. In those studies, the 
effect of rimonabant on rates of responding was mixed, 
with two of the three studies showing no change in re-
sponse rate (Le Foll and Goldberg 2004; Zaniewska et al. 
2006). Furthermore, in the current study, 0.01 mg/kg CP 
55,940 partially substituted for the training dose and en-
hanced responding to a low dose of nicotine. However, 
in the operant-conditioning study by Zaniewska et al. 
(2006), pretreatment with a higher dose of CP 55,940 (0.1 
mg/kg) had no effect on nicotine discrimination perfor-
mance or rate of responding. 
There are several possible reasons for the differences 
between the present studies and those just described. 
Figure 4. Panel a shows initial elevation scores for rats trained with 0.01 mg/kg then 0.03 mg/kg CP 55,940 as a positive drug fea-
ture. Panel b shows locomotor activity during training. For both panels, ^ denotes a significant main effect of Drug without an 
interaction 
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For instance, the dose of nicotine used as an SD was 0.4 
mg/kg; the present study used 0.2 mg/kg nicotine as 
the CS training dose. The 0.4 mg/kg dose during the nic-
otine generalization test did not evoke a CR (i.e., dipper 
entries were at saline levels), a finding consistent with 
the suggestion that the interoceptive stimulus effects of 
0.2 mg/kg differ from 0.4 mg/kg. In Murray and Bevins 
(2007a), 0.4 mg/kg also did not generalize to 0.2 mg/kg 
nicotine. Additionally, extinction of the 0.4 mg/kg nico-
tine CS proceeded more slowly than the 0.2 mg/kg CS 
(Murray and Bevins 2007b). Finally, in the operant drug 
discrimination task, rats trained on 0.4 mg/kg learned 
the discrimination faster than rats trained on 0.2 mg/
kg (cf. Chance et al. 1977). Another reason may be that 
previous research with CP 55,940 or rimonabant and 
the stimulus effects of nicotine used the two-lever oper-
ant-discrimination task with separate schedules of rein-
forcement in force depending on drug state. The present 
research used a Pavlovian discriminated goal-tracking 
task in which the reinforcer was made available inde-
pendent of responding. If this distinction eventuates to 
be important, then present results are the second neuro-
pharmacological distinction found between the stimulus 
effects of nicotine as a CS versus an SD. The first one was 
described by Murray and Bevins (2007a). In that study, 
the N-methyl-d-aspartate receptor channel blocker MK-
801 attenuated conditioned responding evoked by a nic-
otine CS. In contrast, nicotine-appropriate operant re-
sponding was unchanged after MK-801 pretreatment in 
Zakharova et al. (2005) and Kim and Brioni (1995). 
Because the interoceptive effects of CP 55,940 en-
hanced conditioned responding to the nicotine CS, we 
hypothesized that this cannabinoid agonist would also 
function as a CS. However, after twice the training as 
that for nicotine, there was still no suggestion that con-
ditioned responding was coming under control of the 
CP 55,940 drug state. The subset of rats subsequently 
switched to nicotine quickly acquired the Pavlovian dis-
crimination. Thus, CP 55,940 shares some stimulus ef-
fects with nicotine as measured by partial substitution 
for the nicotine CS and its enhancement of conditioned 
responding to a low non-training dose of nicotine. The 
stimulus effects of 0.01 mg/kg CP 55,940 itself, how-
ever, were not sufficient to function as a CS for access to 
water. Notably, switching to nicotine training revealed 
the locomotor-inhibiting effects of early nicotine expo-
sure and suggests no cross-tolerance developed with CP 
55,940 exposure. 
Research from our laboratory has shown that thus 
far, drugs other than nicotine (i.e., amphetamine, caf-
feine, and chlordiazepoxide) do not readily come to con-
trol a CR when trained as a CS (Murray et al. 2007; Pal-
matier and Bevins 2007). In contrast, up to this point, 
every drug state tested by us has functioned as a pos-
itive drug feature occasioning when a discrete CS will 
be reinforced. That list includes amphetamine, bupro-
pion, caffeine, chlordiazepoxide, cocaine, methamphet-
amine, and nicotine (Murray et al. 2007; Palmatier and 
Bevins 2007; Reichel et al. 2007b; Wilkinson et al. 2008). 
Further, midazolam was an effective positive drug fea-
ture disambiguating a context CS-shock US pairings in 
rats (Maes et al. 1996). Midazolam, as well as amphet-
amine, were effective when trained as positive fea-
tures for light CS–food pellet pairings in rats (Maes and 
Vossen 1997). Troisi and Akins (2004) found that a co-
caine-positive feature facilitated conditioned approach 
behavior to a wood block CS paired with copulatory 
opportunity in male quail. Finally, drugs such as mor-
phine and fentanyl serve as positive drug features that 
signal when a saccharin solution will be paired illness 
(Jaeger and Mucha 1990; Skinner et al. 1998). Although 
not an exhaustive list, clearly there is evidence that drug 
states function as positive features. As such, we trained 
CP 55,940 as a positive drug feature. Even though there 
was clear evidence of biological activity of the CP 55,940 
in the present study (e.g., altering activity, substituting 
for nicotine, etc.), the drug did not reliably modulate (fa-
cilitate) conditioned responding to the light. This is the 
first example of a drug with demonstrable SD effects (cf. 
De Vry and Jentzsch 2003; Mauler et al. 2002) not func-
tioning as a positive feature in our discriminated goal-
tracking task. 
One of the compounds that functioned as a positive 
feature in earlier research was chlordiazepoxide (e.g., 
Palmatier and Bevins 2008). The authors found that CR 
topography changed when using a white noise rather 
than a light CS. Rats were holding their heads in the 
dipper receptacle longer rather than more often. There is 
a detailed literature showing that conditioned response 
form can vary as a function of stimulus modality (e.g., 
Bevins and Ayres 1991; Farwell and Ayres 1979). To de-
termine whether the more-maintained head-poke CR 
developed to the light CS on CP 55,940 sessions, we as-
sessed the duration (rather than frequency) of dipper 
entries. The pattern of results was no different than that 
for the frequency of entries described in the “Results” 
section. Thus, CP 55,940 did not appear to alter the re-
sponse topography to the light CS in these studies. 
Another potential explanation of the findings involves 
the effects of exogenous cannabinoids on memory func-
tion (for reviews, see Davies et al. 2002; Ranganathan 
and D’Souza 2006). For example, the CB partial agonist, 
Δ9-tetrahydrocannabinol (THC; French 1997; Petitet et 
al. 1998), has been shown to induce performance deficits 
in the radial arm maze (Lichtman and Martin 1996) and 
the Morris water maze (Da Silva and Takahashi 2002) in 
rodents. Administration of rimonabant blocked the def-
icits in both tasks, indicating CB1 receptor specificity of 
memory for the task. Additionally, intrahippocampal 
infusions of CP 55,940 impaired performance in the ra-
dial arm maze (Lichtman et al. 1995), whereas infusions 
of rimonabant enhanced water-maze performance (Rob-
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inson et al. 2008). Perhaps the impairment of acquisi-
tion in the present studies is due to the memory-defi-
cit effects of cannabinoid activation. This seems unlikely 
given our findings that CP 55,940 increased nicotine-ap-
propriate responding, whereas rimonabant decreased 
nicotine-appropriate responding. This pattern is the op-
posite of what would be expected had memory function 
been the primary factor involved in the cannabinoid 
modification of the nicotine CS. In addition, CP 55,940 
effectively served as a SD indicating that it can acquire 
control over behavior (e.g., Wiley et al. 1995a). Overall, 
we are led to the conclusion that at the dose used, and 
within the training conditions of the present research, 
CP 55,940 is not effective as a Pavlovian stimulus (i.e., a 
CS or positive feature). 
Of course, acceptance of this conclusion without the 
above caveat would be premature given that there are 
numerous experimental parameters that could be ma-
nipulated. One example is the training dose. We started 
with 0.01 mg/kg CP 55,940 because this dose signifi-
cantly modified conditioned responding to the nico-
tine CS. The 0.01 mg/kg CP 55,940 is a relatively low 
dose in the cannabinoid literature (cf. De Vry and Jen-
tzsch 2003; Wiley et al. 1995a); a higher dose may be a 
more effective drug feature. Indeed, a weak discrimina-
tion developed when the training dose was increased to 
0.03 mg/kg CP 55,940. However, when the higher dose 
of CP 55,940 served as the drug feature at the start of 
training (i.e., 0.03 mg/kg group) discrimination perfor-
mance was still weak and inconsistent. Although oper-
ant drug discrimination research has shown that 0.03 
mg/kg CP 55,940 was sufficient to function as an SD (De 
Vry and Jentzsch 2003; Mauler et al. 2002), perhaps an 
even higher dose was needed in the Pavlovian positive 
feature task. Another potential parametric change is to 
increase the length of training. We trained the CP 55,940 
CS for twice the number of sessions as the nicotine CS, 
and the CP 55,940 positive features were trained for 
more than twice that of the CP 55,940 CS. Further, De 
Vry and Jentzsch (2003), as well as Mauler et al. (2002), 
showed that rats acquired the 0.03 mg/kg CP 55,940 
operant discrimination in a median of 38 training ses-
sions (cf. to the 120 training sessions in the present CP 
55,940 experiments). It seems unlikely that more train-
ing would have conditioned a stronger discrimination 
in the present studies. 
Overall, the results of the present research indicate a 
mediating role of endocannabinoids in the nicotine CS. 
However, the cannabinoid agonist, CP 55,940, does not 
have Pavlovian stimulus effects using the current pa-
rameters. Because rimonabant does not alter schedule-
controlled responding by a nicotine SD (Cohen et al. 
2002; Le Foll and Goldberg 2004; Zaniewska et al. 2006), 
and because CP 55,940 functions as an effective oper-
ant SD at the doses used here (De Vry and Jentzsch 2003; 
Mauler et al. 2002; Wiley et al. 1995a, b), the current re-
search suggests a potential dissociation between the 
mechanisms mediating operant and Pavlovian stimu-
lus effects of nicotinic and cannabinoidergic compounds 
that warrant further investigation (cf. Murray and Bev-
ins 2007a). 
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